Our findings of mitochondria damage and cardiomyopathy by anti-cancer drugs provide evidence for myocardial Hippo pathway as a putative therapeutic target for limiting cardiotoxicity by chemotherapy, and also hinted the direction in developing the strategy or interventions against chemotherapy-induced cardiomyopathy, such as preventive strategies through targeting cardiac Hippo pathway/YAP activity to preserve myocardial mitochondria and limiting cardiomyopathy. This evidence concerns the gene YAP1 and cardiomyopathy.